Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells.
[primary effusion lymphoma]
Sangivamycin
,
a
structural
analog
of
adenosine
and
antibiotic
exhibiting
antitumor
and
antivirus
activities
,
inhibits
protein
kinase
C
and
the
synthesis
of
both
DNA
and
RNA
.
Primary
effusion
lymphoma
(
PEL
)
is
an
aggressive
neoplasm
caused
by
Kaposi
's
sarcoma
-associated
herpesvirus
(
KSHV
)
in
immunosuppressed
patients
and
HIV-infected
homosexual
males
.
PEL
cells
are
derived
from
post-germinal
center
B
cells
,
and
are
infected
with
KSHV
.
Herein
,
we
asked
if
sangivamycin
might
be
useful
to
treat
PEL
.
We
found
that
sangivamycin
killed
PEL
cells
,
and
we
explored
the
underlying
mechanism
.
Sangivamycin
treatment
drastically
decreased
the
viability
of
PEL
cell
lines
compared
to
KSHV-uninfected
B
lymphoma
cell
lines
.
Sangivamycin
induced
the
apoptosis
of
PEL
cells
by
activating
caspase-
7
and
-
9
.
Further
,
sangivamycin
suppressed
the
phosphorylation
of
Erk
1
/
2
and
Akt
,
thus
inhibiting
activation
of
the
proteins
.
Inhibitors
of
Akt
and
MEK
suppressed
the
proliferation
of
PEL
cells
compared
to
KSHV-uninfected
cells
.
It
is
known
that
activation
of
Erk
and
Akt
signaling
inhibits
apoptosis
and
promotes
proliferation
in
PEL
cells
.
Our
data
therefore
suggest
that
sangivamycin
induces
apoptosis
by
inhibiting
Erk
and
Akt
signaling
in
such
cells
.
We
next
investigated
whether
sangivamycin
,
in
combination
with
an
HSP
90
inhibitor
geldanamycin
(
GA
)
or
valproate
(
valproic
acid
)
,
potentiated
the
cytotoxic
effects
of
the
latter
drugs
on
PEL
cells
.
Compared
to
treatment
with
GA
or
valproate
alone
,
the
addition
of
sangivamycin
enhanced
cytotoxic
activity
.
Our
data
thus
indicate
that
sangivamycin
may
find
clinical
utility
as
a
novel
anti-
cancer
agent
targeting
PEL
.
Diseases
Validation
Diseases presenting
"lymphoma"
symptom
adrenal incidentaloma
alpha-thalassemia
carcinoma of the gallbladder
cushing syndrome
dedifferentiated liposarcoma
erdheim-chester disease
erythropoietic protoporphyria
esophageal adenocarcinoma
esophageal carcinoma
familial hypocalciuric hypercalcemia
focal myositis
hirschsprung disease
hodgkin lymphoma, classical
kabuki syndrome
liposarcoma
locked-in syndrome
monosomy 21
oculocutaneous albinism
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
wiskott-aldrich syndrome
This symptom has already been validated